Chemistry: molecular biology and microbiology – Virus or bacteriophage – except for viral vector or...
Reexamination Certificate
2006-07-18
2006-07-18
Housel, James (Department: 1648)
Chemistry: molecular biology and microbiology
Virus or bacteriophage, except for viral vector or...
C435S239000, C435S320100, C435S069300, C435S455000, C435S456000, C435S457000, C435S461000
Reexamination Certificate
active
07078218
ABSTRACT:
Provided herein are methods for producing alphavirus replicon particles in high yield; replicon RNAs are electroporated into permissive cells, where the cells are at a relatively high density, together with at least one helper nucleic acid providing the necessary functions for packaging. After a growth period in appropriate medium, alphavirus replicon particles are harvested from the surfaces of the cells in which they were produced using a salt wash in which the salt concentration is from about 0.2 to about 5 M sodium chloride, calcium chloride, magnesium chloride, potassium chloride, ammonium acetate, ammonium bicarbonate, among others. After dilution, if necessary, the particles can be purified by a suitable chromatographic technique.
REFERENCES:
patent: 4650764 (1987-03-01), Temin et al.
patent: 4708871 (1987-11-01), Geysen
patent: 5091309 (1992-02-01), Schlesinger et al.
patent: 5185440 (1993-02-01), Davis et al.
patent: 5217879 (1993-06-01), Huang et al.
patent: 5505947 (1996-04-01), Johnston et al.
patent: 5639650 (1997-06-01), Johnston et al.
patent: 5643576 (1997-07-01), Johnston et al.
patent: 5703057 (1997-12-01), Johnston et al.
patent: 5726022 (1998-03-01), Burmer
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5811407 (1998-09-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5827658 (1998-10-01), Liang et al.
patent: 5831016 (1998-11-01), Wang et al.
patent: 5843723 (1998-12-01), Dubensky, Jr. et al.
patent: 5853719 (1998-12-01), Nair et al.
patent: 5958738 (1999-09-01), Lindemann et al.
patent: 5989553 (1999-11-01), Johnston et al.
patent: 6008035 (1999-12-01), Johnston et al.
patent: 6015686 (2000-01-01), Dubensky, Jr. et al.
patent: 6015694 (2000-01-01), Dubensky, Jr. et al.
patent: 6146874 (2000-11-01), Zolotukhin et al.
patent: 6156558 (2000-12-01), Johnston et al.
patent: 6190666 (2001-02-01), Garoff et al.
patent: 6194191 (2001-02-01), Zhang et al.
patent: 6197502 (2001-03-01), Renner et al.
patent: 6224879 (2001-05-01), Sjoberg et al.
patent: 6242259 (2001-06-01), Polo et al.
patent: 6261570 (2001-07-01), Parker et al.
patent: 6267967 (2001-07-01), Johnston et al.
patent: 6306388 (2001-10-01), Nair et al.
patent: 6329201 (2001-12-01), Polo et al.
patent: 6342372 (2002-01-01), Dubensky, Jr. et al.
patent: 6376236 (2002-04-01), Dubensky, Jr. et al.
patent: 6391632 (2002-05-01), Dubensky, Jr. et al.
patent: 6426196 (2002-07-01), Dubensky, Jr. et al.
patent: 6451592 (2002-09-01), Dubensky, Jr. et al.
patent: 6485958 (2002-11-01), Blanch et al.
patent: 6495143 (2002-12-01), Lee et al.
patent: 6521235 (2003-02-01), Johnston et al.
patent: 6583121 (2003-06-01), Johnston et al.
patent: 6767699 (2004-07-01), Polo et al.
patent: 6770283 (2004-08-01), Garoff et al.
patent: 6783939 (2004-08-01), Olmsted et al.
patent: 6844188 (2005-01-01), MacDonald et al.
patent: 2002/0018766 (2002-02-01), Roberts et al.
patent: 2002/0102273 (2002-08-01), Grieve et al.
patent: 2002/0141975 (2002-10-01), Olmsted et al.
patent: 2003/0021766 (2003-01-01), Vadjy et al.
patent: 2003/0091591 (2003-05-01), Xiong et al.
patent: 2003/0119182 (2003-06-01), Smith et al.
patent: 2003/0148262 (2003-08-01), Polo et al.
patent: 2003/0232035 (2003-12-01), Dubensky et al.
patent: 2004/0029278 (2004-02-01), Dubensky et al.
patent: 2004/0166573 (2004-08-01), Smith et al.
patent: 2004/0235133 (2004-11-01), Frolov et al.
patent: 2005/0054107 (2005-03-01), Chulay et al.
patent: 2005/0123555 (2005-06-01), Olmsted et al.
patent: WO 92/10578 (1992-06-01), None
patent: WO 95/27044 (1995-10-01), None
patent: WO 95/31565 (1995-11-01), None
patent: WO 96/17072 (1996-06-01), None
patent: WO 96/37220 (1996-11-01), None
patent: WO 96/37616 (1996-11-01), None
patent: WO 99/07834 (1999-02-01), None
patent: WO 99/08706 (1999-02-01), None
patent: WO 00/39318 (2000-07-01), None
patent: WO 00/61772 (2000-10-01), None
patent: WO 02/20721 (2002-03-01), None
patent: WO 03/023026 (2003-03-01), None
patent: WO 04/085660 (2004-10-01), None
Pushko, P. et al. Replicon-Helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo (1997) Virology, vol. 239, pp. 389-401.
Polo, J.M. et. al. Stable alphavirus packaging cell lines for Sindbis virus- and Semliki forest virus-derived vectors (1999) Proc. Natl. Acad. Sci. vol. 96, pp. 4598-4603.
Lijestrom, P. et. al. In vitro mutagenesis of a full-length CDNA clone of Semliki Forest virus: the small 6,000-molecular weight membrane protein modulates virus release (1991) J. Virol. 65:4107-4113.
Rayner, J.O. et. al. Alphavirus vectors and vaccination (2002) Rev. Med. Virol. 12:279-296.
Bell, J.W. et. al. Effect of low-NaCl medium of the envelope glycoproteins of Sindbis virus (1978) Journal of Virology, vol. 25(3), pp. 764-769.
Bredenbeek, P.J. et. al. Sindbis virus expression vectors: Packaging of (1993) J. Virol. 67(11) pp. 6439-6446.
Technical Bulletin No. 166: RiboMAX Large Scale RNA Production Systems—SP6 and T7; Promega Corporation; pp. 1-11; Revised Sep. 2001—On http://www.promega.com/tbs/tb166/tb166.pdf on Nov. 4, 2004.
Balasuriya et al. (Feb. 2002) “Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses”;Vaccine20:1609-1617.
Bell et al. (Mar. 1978) “Effect of Low-NaCl Medium on the Envelope Glycoproteins of Sindbis Virus”;J. Virol.25(3):764-769.
Bernard et al. (2000) “Mutations in the E2 Glycoprotein of Venezuelan Equine Encephalitis Virus Confer Heparan Sulfate Interaction, Low Morbidity, and Rapid Clearance from Blood of Mice,”Virology276:93-103.
Casimiro et al. (Jan. 2002) “Vaccine-induced immune responses in rodents and nonhuman primates by use of a humanized immunodeficiency virus type 1 pol gene”;J. Virol.76:185-195.
Davies et al. (1991), “Attenuating Mutations in the E2 Glycoprotein Gene of Venezuelan Equine Encephalitis Virus: Construction of Single and Multiple Mutants in a Full-Length cDNA Clone,”Virology183:20-31.
Davies et al. (1986) “A Single Nucleotide Change in the E2 Glycoprotein Gene of Sindbis Virus Affects Penetration Rate in Cell Culture and Virulence in Neonatal Mice,”Proc. Natl. Acad. Sci. USA83:6771-6775.
Frolov et al. (1996) “Alphavirus-based expression vectors: Strategies and applications”;Proc. Natl. Acad. Sci.USA93:11371-11377.
Geisbert et al. (May 2002) “Evaluation in Nonhuman Primates of Vaccines against Ebola Virus”;Emerging Infect. Dis.8(5):503-507.
Golzio et al. (Jun. 2002) “Cell Synchronization Effect on Mammalian Cell Permeabilization and Gene Delivery by Electronic Field,”Biochim. Biophys. Acta1563:23-28.
Hahn et al. (1992) “Infectious Sindbis Virus Transient Expression Vectors for Studying Antigen Processing and Presentation,”Proc. Natl. Acad. Sci. USA89:2679-2683.
Heiser et al. (Feb. 2002) “Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors,”J. Clin. Inv.109(3):409-417.
Hevey et al. (1998) “Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates”;Virology251:28-37.
Hill et al., (1997) “RNA-RNA recombination in Sindbis virus: role of the 3′ conserved motif, poly(A) tail, and nonviral sequences of template RNAs in polymerase recognition and template switching,”J. Virol.71:2693-2704.
Johnston et al., (1988) “Selection for Accelerated Penetration in Cell Culture Coselects for Attenuated Mutants of Venezuelan Equine Encephalitis Virus,”Virology162:437-443.
Kinney et al. (1989) “The Full Length Nucleotide Sequences of the Virulent Trinidad Donkey Strain of Venezuelan Equine Encephalitis Virus and Its Atte
Alterson Harold
Butler Kim
Dryga Sergey
Kamrud Kurt
Maughan Maureen F.
AlphaVax, Inc.
Housel James
Salvoza M. Franco
LandOfFree
Alphavirus particles and methods for preparation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alphavirus particles and methods for preparation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alphavirus particles and methods for preparation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536692